期刊文献+

骨肉瘤组织中E-cad、MMP-13的表达及其与临床病理特征的关系

Expression of E-cad and MMP-13 in Osteosarcoma Tissues and Their Relationship with Clinicopathological Features
下载PDF
导出
摘要 目的 探讨上皮型E-钙粘蛋白(E-cad)、基质金属蛋白酶-13(MMP-13)在骨肉瘤组织中的表达及其与临床病理特征的关系。方法 选取经外科手术治疗的骨肉瘤患者58例作为研究对象,采集患者术后病理组织,并采用免疫组化法检测骨肉瘤组织中E-cad、MMP-13的表达,分析其与患者临床病理特征的关系。结果 骨肉瘤组织中的E-cad高表达低于癌旁组织、MMP-13高表达高于癌旁组织,差异有统计学意义(P<0.05)。骨肉瘤患者组织中E-cad、MMP-13高表达与不同TNM分期、淋巴结转移有关(P<0.05),与不同性别、年龄、组织学分级无关(P>0.05);Spearman相关分析结果显示,骨肉瘤组织中E-cad表达与TNM分期、淋巴结转移呈负相关(γ<0,P<0.05);MMP-13表达与TNM分期、淋巴结转移呈正相关(γ>0,P<0.05)。Kaplan-Meier生存分析显示,E-cad高表达的总生存率高于无或低表达,差异有统计学意义(Log Rankχ^(2)=4.753,P=0.029);MMP-13高表达的总生存率低于无或低表达,差异有统计学意义(Log Rankχ^(2)=8.135,P=0.004)。结论 骨肉瘤组织中E-cad呈无或低表达,MMP-13呈高表达,E-cad、MMP-13表达与临床病理特征密切相关,可作为临床评估骨肉瘤患者预后的生物标志物。 Objective To investigate the expression of epithelial E-cadherin(E-cad)and matrix metalloproteinase-13(MMP-13)in osteosarcoma tissues and their relationship with clinicopathological features.Methods 58 patients with osteosarcoma who underwent surgical treatment were selected as the research subjects.The postoperative pathological tissues of patients were collected,the expression of E-cad and MMP-13 in osteosarcoma tissues was detected by immunohistochemistry,and their relationship with clinicopathological features of patients was analyzed.Results The high expression of E-cad in osteosarcoma tissues was lower than that in adjacent tissues,and the high expression of MMP-13 was higher than that in adjacent tissues,the difference was statistically significant(P<0.05).High expression of E-cad and MMP-13 in tissues of osteosarcoma patients was associated with different TNM stages and lymph node metastasis(P<0.05).There was no statistical significant difference in sex,age and histological grade(P>0.05);through Spearman correlation analysis,the results showed that,the expression of E-cad in osteosarcoma tissues was negatively correlated with TNM stage and lymph node metastasis(γ<0,P<0.05);the expression of MMP-13 was positively correlated with TNM stage and lymph node metastasis(γ>0,P<0.05);Kaplan-Meier survival analysis showed that the overall survival rate of E-cad with high expression was higher than that with no or low expression,and the difference was statistically significant(Log Rankχ^(2)=4.753,P=0.029);the overall survival rate of MMP-13 with high expression was lower than that with no or low expression,and the difference was statistically significant(Log Rankχ^(2)=8.135,P=0.004).Conclusion There is no or low expression of E-cad and high expression of MMP-13 in osteosarcoma tissues.The expression of E-cad and MMP-13 is closely related to clinicopathological features,which can be called biomarkers for clinical evaluation of the prognosis of osteosarcoma patients.
作者 张立全 齐文斐 ZHANG Liquan;QI Wenfei(Kaifeng People's Hospital,Kaifeng,475000)
出处 《实用癌症杂志》 2023年第11期1801-1804,1809,共5页 The Practical Journal of Cancer
关键词 骨肉瘤 上皮型E-钙粘蛋白 基质金属蛋白酶-13 临床病理特征 Osteosarcoma Epithelial E-cadherin Matrix metalloproteinase-13 Clinicopathological features
  • 相关文献

参考文献15

二级参考文献93

  • 1张伊,杨林,魏立彬.ROS-AMPK信号通路在肿瘤发生发展中的关系[J].世界最新医学信息文摘,2019,0(99):45-47. 被引量:3
  • 2郭卫,杨毅.骨肉瘤的诊断治疗进展[J].继续医学教育,2006,20(12):27-31. 被引量:4
  • 3熊松柏,杨康.基质金属蛋白酶(MMPs)与肿瘤转移相关性研究进展[J].临床和实验医学杂志,2006,5(11):1850-1851. 被引量:17
  • 4Dahlin DC,Coventry MB. Osteogenic sarcoma. A study of six hundred cases[J].J Bone Joint Surg Am, 1967,49 (1) : 101-110.
  • 5Enneking WF. An abbreviated history of orthopaedic on- cology in North America[J].Clin Orthop Relat Res, 2000 (374) : 115-124.
  • 6Hudson M,Jaffe MR,Jaffe N, et al. Pediatric osteosarco- ma : therapeutic strategies, results, and prognostic factors derived from a 10-year experience[J]. J Clin Oneol, 1990, 8(12) :1988-1997.
  • 7Bacci G, Avella M, Capanna R, et al. Neoadjuvant chemo- therapy in the treatment of osteosarcoma of the extremi- ties:preliminary results in 131 cases treated preoperative- ly with methotrexate and eisdiamminoplatinum[J]. Ital J Orthop Traumatol, 1988,14 ( 1 ):23-39.
  • 8Bacci G, Picci P, Ferrari S, et al. Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy:results of two sequential studies[J]. J Chemother, 1993,5(4) : 237-246.
  • 9Delepine N,Delepine G,Bacci G,et al. Influence of metho- trexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature [J].Cancer, 1996,78(10) : 2127-2135.
  • 10Bacci G, Ferrari S, Picci P, et al. Methotrexate serum con- centration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs[J]. J Che- mother, 1996,8(6) :472-478.

共引文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部